New York, New York–(Newsfile Corp. – January 5, 2026) – Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the […]

Tel Aviv, Israel–(Newsfile Corp. – January 5, 2026) – Kardome, a pioneer in voice AI solutions, today introduced Cognition AI, a breakthrough technology designed to make on-device voice interfaces truly intelligent and bring natural voice interaction to cars, homes, and the workplace, where traditional systems often struggle. Cognition AI, combined with Spatial Hearing AI, serves

Calgary, Alberta–(Newsfile Corp. – January 5, 2026) – Simply Solventless Concentrates Ltd. (TSXV: HASH) (“SSC“) is pleased to announce the appointment of seasoned executive Charles Vennat to its board of directors. Charles is an accomplished CEO and corporate director with significant experience leading complex manufacturing, consumer packaged goods and regulated cannabis businesses. Charles currently serves

San Diego, California–(Newsfile Corp. – January 5, 2026) – The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY): (i) securities between August 7, 2025 and September 29, 2025, inclusive (the “Class Period”); and/or (ii) common stock pursuant and/or traceable to Firefly Aerospace’s offering

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 5, 2026 / Fully financed through Q1, tech pioneer SMX (NASDAQ:SMX) has begun 2026 with an eye on accelerating adoption of its Plastic Cycle Token and verification platform As businesses worldwide face mounting pressure to meet carbon-reduction targets and comply with a growing patchwork of

(NASDAQ:ZBIO), – Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare – – Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints – – Obexelimab was well tolerated and no new safety signals were observed – – Zenas

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) GlobeNewswire January 05, 2026 – Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare – – Obexelimab also met and demonstrated statistically significant activity on all

NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Six Flags Entertainment Corporation ("Six Flags" or the "Company") (NYSE:FUN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by

NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" or the "Company") (NYSE:PRGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

NEW YORK CITY, NY / ACCESS Newswire / January 5, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation ("Integer" or the "Company") (NYSE:ITGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are